Obvious Ventures Leads $20M Series A for Mithrl’s Biomedical AI
Fundraise Insider tracks newly funded startups each week and delivers verified sales leads of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.
Mithrl, a San Francisco company building a software platform for drug research, has raised $20 million. Obvious Ventures led the Series A round. Headline, AGI House, and a group of pharma executives also took part.
The money will fund the second generation of the company’s platform, known as Mithrl-1. The system pairs a proprietary biomedical world model with an agentic layer that handles model routing, token optimization, and content orchestration. An early access program for the new version opens on September 21.
Co-founder and CEO Vivek Adarsh started the California company three years ago after losing his grandfather to acute kidney disease, a condition that at the time had no FDA-approved treatments. The stated goal is to help R&D teams get from an initial idea to an IND filing in half the usual time.
Mithrl’s approach differs from many AI drug discovery tools in one important way. Its agents reason only over validated biology, drawn from decades of peer-reviewed research along with public and partnered datasets, rather than searching across a broad pool of unverified information. The company says this keeps compute costs down. A recent benchmark it shared showed its infrastructure used 45% fewer tokens than standard workflows running the same frontier models without customization.
The platform runs inside each customer’s own environment and works across existing frontier models. Biopharma teams can layer in their proprietary data and pipelines, then build and manage their own biomedical agents. When new studies are published, Mithrl updates its knowledge base and pushes those changes out to customers. Every hypothesis the system generates comes with its sources and a confidence score that shows what was read, how the conclusion was reached, and how much to trust it.
Several top-10 pharmaceutical companies, clinical-stage biotech firms, and genomics platform partners already use the product. One named customer is Elephas Biosciences, which develops an ex vivo tumor profiling platform. The two companies announced a scientific collaboration in April to combine functional tumor profiling with AI analysis in search of new immunotherapy response signals. Mithrl expects to announce more customer deals in the fourth quarter.
The company reports that discoveries made with its platform have contributed to more than half a dozen customer-owned patent filings. It also claims its biomedical world model returns 16 times more primary evidence per answer than frontier models on their own, and that it scored 0.96 for scientific correctness in expert-rated biomedical benchmarks, against 0.6 without the platform.
Mithrl currently employs about 30 people. The first priority for the new capital is hiring to keep up with demand for deployments inside large organizations, followed by expansion into more therapeutic areas. The near-term focus is on the disease areas its customers work on most: immune-related diseases, oncology, diabetes, metabolic disease, and cardiovascular disease.
Service providers and software vendors that sell into biopharma research teams can receive verified contacts at newly funded life science startups every week through Life Science Lead Generation.